A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome

Detalles Bibliográficos
Autores principales: Komrokji, Rami S., Carraway, Hetty E., Germing, Ulrich, Wermke, Martin, Zeidan, Amer M., Fu, Eric, Rüter, Björn, Burkard, Ute, Osswald, Annika, Foran, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614517/
https://www.ncbi.nlm.nih.gov/pubmed/35734924
http://dx.doi.org/10.3324/haematol.2021.280500
_version_ 1784820212750614528
author Komrokji, Rami S.
Carraway, Hetty E.
Germing, Ulrich
Wermke, Martin
Zeidan, Amer M.
Fu, Eric
Rüter, Björn
Burkard, Ute
Osswald, Annika
Foran, James M.
author_facet Komrokji, Rami S.
Carraway, Hetty E.
Germing, Ulrich
Wermke, Martin
Zeidan, Amer M.
Fu, Eric
Rüter, Björn
Burkard, Ute
Osswald, Annika
Foran, James M.
author_sort Komrokji, Rami S.
collection PubMed
description
format Online
Article
Text
id pubmed-9614517
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-96145172022-11-03 A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome Komrokji, Rami S. Carraway, Hetty E. Germing, Ulrich Wermke, Martin Zeidan, Amer M. Fu, Eric Rüter, Björn Burkard, Ute Osswald, Annika Foran, James M. Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-06-23 /pmc/articles/PMC9614517/ /pubmed/35734924 http://dx.doi.org/10.3324/haematol.2021.280500 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Letter to the Editor
Komrokji, Rami S.
Carraway, Hetty E.
Germing, Ulrich
Wermke, Martin
Zeidan, Amer M.
Fu, Eric
Rüter, Björn
Burkard, Ute
Osswald, Annika
Foran, James M.
A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
title A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
title_full A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
title_fullStr A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
title_full_unstemmed A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
title_short A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
title_sort phase i/ii multicenter, open-label, dose escalation and randomized trial of bi 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614517/
https://www.ncbi.nlm.nih.gov/pubmed/35734924
http://dx.doi.org/10.3324/haematol.2021.280500
work_keys_str_mv AT komrokjiramis aphaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT carrawayhettye aphaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT germingulrich aphaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT wermkemartin aphaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT zeidanamerm aphaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT fueric aphaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT ruterbjorn aphaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT burkardute aphaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT osswaldannika aphaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT foranjamesm aphaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT komrokjiramis phaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT carrawayhettye phaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT germingulrich phaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT wermkemartin phaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT zeidanamerm phaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT fueric phaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT ruterbjorn phaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT burkardute phaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT osswaldannika phaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome
AT foranjamesm phaseiiimulticenteropenlabeldoseescalationandrandomizedtrialofbi836858inpatientswithloworintermediate1riskmyelodysplasticsyndrome

Ejemplares similares